Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pulling SP down at Market Open to trigger 4 'Stop Loss Orders' and then Selling those 4s at 5 or 6 sounds a lot like "buy low and sell higher"
Do you feel that dumping 3.6 million shares at the Open accurately reflects a day's Trading?
Or does it reflect someone wanting to manipulate the price downward? It could be a Market Maker or it could be shareholder with an agenda.
Wouldn't a legitimate shareholder who decided to Sell 3.6 million shares today want to get as much money as possible from that sale?
Yesterday there was 10 to 12 million shares on the 5 Bid Size. Why dump 3.6 million shares in the Opening seconds when there are only 1.9 million shares on the 5 Bid Size unless your goal is to drop the SP not get the most money out of your sale?
At 10:16 this morning, with a 5 Bid Size of 4.7 million shares & a 6 Ask Size of 11.7 million shares and no transactions since the 9:30 dump, I ran a test to see what would happen to a Buy Order at 6 for 100k shares. It was filled at .00055, so it was classified as a 'Neutral Trade' rather than a Buy.
38 seconds after my Trade filled a Sell for 140k shares at .0005 hit the Tape.
A company's share price does not necessarily reflect its value
<<<<<<<< NO reputable and successful company will even pay $12.5 million >>>>>>>>>
SiriusXM traded at $69 in March of 2000, was it worth that much, probably not but rapid growth had propelled it upward . In February 2009 SIRI traded at 5 cents, was it worth that little, no but financial debt issues had beaten it down.
A company wanting to enter the PEMF/PSWT market can hire knowledgeable engineers and build a product themselves or Acquire or Partner with a company that already has the technology/products.
" The average cost to bring a medical device to market through the 510 (k) pathway is $31 million compared to the PMA pathway with average costs of $94 million."
BIEL has 5 FDA Clearances for PEMF/PSWT Medical Devices and 3 of those expensive FDA Indications are for OTC Medical Device Marketing, something no one else currently has.
Still not getting it
There is no market for billions of shares from Convertible Loan conversions unless BIEL has a positive story and is profitable.
Chartmaster with 1,478 Followers disagrees with you
"See Chart! It turned bullish beginning of June when price popped above the 50 day MA, now the 50 day MA is rising! Classic bearish to Bullish reversal imo! Ready for it to run again with all OTC! OTC is back!"
LOL, so now BIEL regaining 'Pink Current' is a bad thing????
Some must be very Dizzy from all of the Spinning.
So let me get this straight .....
<<<<<<< He is IN now and he will do or say anything to protect his personal investment >>>>>>>>
In your Opinion, Dr Staelin, a well respected educator teaching at Duke University and Carnegie-Mellon University for over 50 years, who has been associated with BIEL since 2005, is ignoring his responsibilities as 'Chairman of the Board' at BIEL and making decisions based on protecting his "personal investment".
Wow, that is quite the accusation. Unfortunately it does not align with the facts. Anyone with real evidence of Dr Staelin failing to perform his COB duties should advise FINRA.
IMO, the truth is that the only path for any of the large lenders to get their Loans repaid is BIEL becoming profitable.
Dr Staelin's field is 'Marketing Science'. He knows BIEL and its products very well.
He developed the UK Social Media Campaign that brought BIEL its highest annual revenue, $2.33 million in 2015.
He invested $268k in new Interest Only Loans to BIEL in Q4 2022 after the low revenue of Q3.
He invested $75k in new Interest Only Loans to BIEL in Q1 2023 after the low revenue of Q4 2022.
He is committed to seeing BIEL through to profitability and feels it is achievable based on his 50 years experience in the Science of Marketing.
How is making hundreds of thousands of dollars in new loans to BIEL "protecting his personal investment" if BIEL is headed for BK as some declare on a daily basis?
I will go with the Opinion of the guy who has a doctoral degree in Marketing Science and is placing his own money behind that opinion every Quarter.
Good Grief, Dr Staelin is the COB, he knows what the "sales numbers" are before the revenue hits the BIEL bank account
<<<<<<<< Wonder how happy (sad?) he is right now about doing those loans after seeing the most recent sales numbers >>>>>>>>
Well that is one opinion, but I will go with the opinions of those who are not anonymous:
<<<<<<<<<<<< waste of time and money >>>>>>>>>>>
* FDA - says ActiPatch and RecoveryRx are safe and effective pain relievers
* CE Mark - Approved ActiPatch and RecoveryRx to be sold in 34 countries
* Cofepris (Mexico's FDA) - Approved RecoveryRx to be sold in Mexico
* Adcock Ingram - added actiPatch to their healthcare products lineup
* STADA - added ActiPatch to their MENA healthcare products lineup
* KT Health - recently introduced a new 720 hour Wave product in the UK
* UCSD - thought enough of RecoveryRx to sponsor a phantom limb study
And by the way
<<<<<<< saying "they didn't dilute" is kind of meaningless >>>>>>>
Nope, last dilution was January 2022 by St John's. In February 2022 St Johns started using the proceeds from that dilution to fund BIEL with new, Non-Convertible Loans. Every other Convertible Loan that matured in 2022 was Rolled Over. Both Whelan family and non-family lenders want to see BIEL succeed.
Any of those Lenders who had 2022 maturing loans could have demanded repayment in cash or shares and BIEL would have needed to repay them or face a lawsuit.
I will go with Dr Staelin's commitment to see BIEL succeed over the opinion of any anonymous message board poster
"Richard Staelin is the Gregory Mario and Jeremy Mario Professor Emeritus of Business Administration at the Fuqua School of Business, Duke University. He joined Duke in 1982 after teaching at Carnegie-Mellon University for 13 years. He has also been on the faculties of the Australian Graduate School of Management and the University of Chicago. He was Editor of Marketing Science and President of ISMS. He has won best paper awards at Marketing Science, JMR and JM and was awarded the Converse Award and the AMA Best Educators Award. He is an inaugural fellow in ISMS and the AMA and a fellow in INFORMS. He was awarded the best teaching award for the DKU program in 2016."
"After serving as an administrator for many years, he went back to the classroom teaching the core marketing course. He also served on the board of two small start-ups, one involved with marketing a medical device, the other developing a unique survey instrument to better assess patient experience."
Not a barn burner quarter but moving in the right direction compared to Q3 & 4 of 2022
KT probably ordered the 720 hour Wave for the UK, first area to get the new Wave. As they roll out this new product to more areas orders should increase.
Adcock Ingram is not just doing business in South Africa they cover 14 markets on the African Continent. In 2020 they expanded their distribution capabilities by bringing in a partner for product delivery.
BIEL had no dilution from Convertible Loans in Q1 2023.
Dr Staelin made 4 new Loans in Q1 totaling $75k. All of these Loans were interest only, no conversion option.
Keith Nalepka is still shown as owning 100 million shares in the Q1 Financials.
$158k Revenue for Q1 2023
The only thing Sales-Track shows is that anyone who quotes Sales-Track is full of BS
BIEL holding on to 6 despite MM Monkey Shines today.
Only 77,850 shares sold at 5 today out of a 7.2 million share Total Volume.
Afraid this is Far From "Straight"
Sree Koneru leaving is GOOD - Sree got married and his wife was pregnant, he needed more income that BIEL could not supply, he is still doing consulting work for BIEL
Keith Nalepka leaving is GOOD - Keith is still on BIEL's BOD which controls all important decisions
2022 Q3 and Q4 abysmal 100K in TOTAL GLOBAL SALES is GOOD
2023 Q1 is LATE is GOOD
BIEL being a forfeited corporation in Maryland is GOOD
BIEL trading at the same level as 2017 is GOOD - Not sure what is being implied here, BIEL has always been a news driven stock, in January 2017 BIEL hit a Low of .0002, in February BIEL shot up to .003 upon news of two significant FDA Clearances, Knee and Foot Pain Relief.
BIEL being downgraded on OTC markets is GOOD
BIEL NOT being promoted in any investor publications AT ALL by a failure of a PR guy is GOOD - It is a long established fact that BIEL does not have the resources for advertising products, OEM and Distributor promotion is in their contracts, we saw Adcock Ingram's TV and Trade Fair promotions last month,
BIEL's only source of income is donation money from Staelin in the form of convertible notes is GOOD - Dr Staelin rejoined the BIEL BOD in 2020 and has made numerous loans to BIEL since then, none of which were Convertible into BIEL shares, all were Interest Only Loans.
Must be looking at the wrong stock
BIEL currently has the following Trading stats for today:
Up 20 percent
Buys = 5 million shares
Sells = 1.2 million shares
Neutral = 8 million shares
Trades @ 6 = 9.5 million shares
Trades @ 7 = 1 million shares
Total Volume = 14.3 million shares
Total Transactions = 34
Orthopedic Surgeon Don Buford says RecoveryRx helps his patients
Anonymous message board poster says BIEL is a scam.
I will go with Dr. Buford's opinion.
Don Buford, MDDon Buford, MD
Orthopedic Surgeon, Regenerative Medicine, Sports Med.Orthopedic Surgeon, Regenerative Medicine, Sports Med.
1w
Just got some very positive feedback on another RecoveryRx patient.
Young guy, diagnosed with costochondritis. He had been struggling with 1 month of pain despite high dose NSAIDs from another clinician.
Orthopedic Surgeon, Sports Medicine Orthopedic Surgeon,
The Sports Medicine Clinic Of North Texas
1999 - Present · 24 yrs 6 mos1999 - Present · 24 yrs 6 mos
Dallas/Fort Worth Area
Don Buford, MD, The Dallas PRP and Stem Cell Institute/ The Sports Medicine Clinic Of North Texas
Dr. Don Buford founded The Dallas PRP and Stem Cell Institute with the goal of creating a clinical research institute whose mission is to provide evidence based orthobiologic treatments for orthopedic pathologies.
By closely following clinical results, Dr. Buford hopes to further refine the indications and treatments for many musculoskeletal conditions. Our Institute's ultimate goal is to maximize our patients' quality of life and minimize their disability and pain from any musculoskeletal condition. We strive to help our patients recover to their desired state of health without a surgical procedure and typically perform use our orthobiologic therapies in office based procedures that take less than an 1 hour. In some cases, we use PRP and bone marrow concentrate stem cell injections to assist, accelerate or augment the healing response after a surgical procedure.
Dr. Buford started his practice in Dallas 20 years ago after completing orthopedic surgery residency at UT Southwestern, Dallas and an orthopedic surgery sports medicine fellowship at the Southern California Orthopedic Institute (www.scoi.com).
Dr. Buford attended Stanford University for the first half of his college career. While at Stanford, he was a member of the baseball team and had a double major in economics and Human Biology. He then transferred to USC where he continued his athletic and academic pursuits.
In 1988 he received the Woody Hayes NCAA Division I Academic All-American Award for being the single most outstanding NCAA Division I male student-athlete.
After graduation from USC, he signed his first professional baseball contract with the Baltimore Orioles and also enrolled at UCLA Medical School.
Dr. Buford played professional baseball as a second baseman and outfielder in the Baltimore Orioles professional organization for 4 years. Dr. Buford's father, Don Sr., played for the Chicago White Sox ('63 -'68) and the Baltimore Orioles ('68-'72) and played in 3 World Series, winning in 1970 over the Cincinnati Reds. Don Sr. is in the Orioles Hall of Fame. Dr. Buford's younger brother, Damon, had an 8 year major league career which included 2 years as the starting center fielder for the Texas Rangers.
After graduating from the UCLA School of Medicine, Dr. Buford completed a 5 year orthopaedic residency at the University of Texas, Southwestern in Dallas. Dr. Buford also completed a one year sports medicine fellowship at the prestigious Southern California Orthopaedic Institute (SCOI) in 1999 where he learned advanced arthroscopy techniques.
Dr. Buford's interest in orthobiologics was a natural outgrowth of his training in minimally invasive surgery.....both are designed to help patients in the simplest, safest way possible.
Since 2008, Dr. Buford has been training clinicians on MSK ultrasound and now orthobiologics as the Director of the MSK Ultrasound and Orthobiologics Course. The course is held twice a year in various locations. Dr. Buford and his course faculty have trained over 1200 clinicians in MSK ultrasound in the past 10 years.
Said the same thing for the last 11 years, Always Wrong
<<<<<<<<<<<<<<< biel is finished >>>>>>>>>>>>>>>>>
That worn out 'Sky is Falling' BS is as fake as 'Sales Track'.
Forgot to mention the $12.50 Paint at the Close Today
18 million in Buys vs 6 million in Sells and a $12.50 Trade at 3:53 drops BIEL to 5 .
Wow, 10.5 million Buy at 7 to open the day!!
Go BIEL !!!
Go BIEL !!!
Go BIEL !!!
Go BIEL !!!
Congrats to All BIEL Longs, UP 40% to 7
Friday is not the best day to PR good news strikeitrich but could happen.
Only 1.19 million Sells on a 27.9 million Total Volume day says it all.
Only 11.1 million shares on the 7 Ask Size after the last trade of the day.
Go BIEL !!!
Go BIEL !!!
Go BIEL !!!
Go BIEL !!!
Thanks Hawk, confirmation that the 720 hour KT Wave is coming to a number of Markets
McDavid is an international sports equipment brand, in business for 53 years.
Sunlight Sports has the Wave at the top of their KT products list:
KT Tape
KT Recovery+ Wave™
KT Recovery+® Ice/Heat Massage Ball
KT Recovery+® Cold Massage Roller
KT Recovery+® Ice/Heat Wrap
KT Performance+® Blister Prevention Tape
KT Performance+® Blister Treatment Patch
KT Tape KT Flex®
KT Performance+® Chafe Safe™ Anti-Chafing Wipes
KT Performance+® Chafe Safe™ Gel Stick
KT Recovery+® Pain Relief Gel Tube
KT Recovery+® Pain Relief Gel Roll-On
KT Recovery+ Recovery Patch®
https://www.sunlightsports.sg/products.html
Yep GG, only problem is someone keeps yanking away the football before BIEL gets over the 6 Goal Line.
Yesterday it was a 10k Sell to close the day. Today it was a 50k Sell.
Buys = 8.8 million shares
Sells = 599k shares
Neutral = 673k shares, LOL more Neutral Trades than Sells
KT will find the right Marketing for the Wave
Having the Wave in their product line allows them to associate the KT brand with an 'FDA Cleared' medical device.
By the way the new KT Wave being advertised in the UK is 720 hours, same amount of therapy as the ActiPatch.
Yes Sir GG, another good day for BIEL, Buys over Sells 4 to 1
The VWAP tells the story. .000595 .
A 10k share Sell ended the day, a $5 Trade.
I tried to keep this fact based hence all of the details and links in my post
<<<<<<<<<< those "short sales" are covered and closed within minutes. >>>>>>>>>>
I can see you did not get the hint based on the undocumented Opinion that you responded with.
Please provide facts or it remains as an Opinion.
Here is another Fact for you, Buys are out numbering Sells again Today:
Buys = 5.1 million shares
Sells = 1.3 million shares
Day #4 with significantly more Buys than Sells, another Fact.
Very well, setting aside speculation, what are the Facts re Naked Shorting and MMs
<<<<<< The daily short report doesn't mean what you think it means >>>>>>
* FINRA's Daily Short Data "reflects the aggregate volume of trades executed and reported as short sales on each trade date.” a Short Trade could be covered same day or 13 days later
* Market Makers don't have to locate shares before Naked Short Selling if they are involved in "bona fide market making activities" this determination is largely self regulated
* FINRA, a Self Regulatory Organization, SRO, is responsible for policing Broker Dealers/Market Makers on the OTC Markets
* Broker Dealers/MMs have up to the Trade Day + 13 Days to closeout their Shorting before it goes to the twice a month FTD list
* Market Makers set the Bid & Ask Prices for the companies they cover
* Investors 'Buy from' & 'Sell to' Market Makers on the OTC Markets
* Market Makers are supposed to keep an inventory of shares for the companies they cover, this can added up to many millions of dollars for MMs like Citadel who cover 7,000 plus companies
Why was Reg SHO implemented?
"Compliance with Regulation SHO began on January 3, 2005. Regulation SHO was adopted to update short sale regulation in light of numerous market developments since short sale regulation was first adopted in 1938 and to address concerns regarding persistent failures to deliver and potentially abusive “naked” short selling."
"Due to continued concerns about failures to deliver, and to promote market stability and preserve investor confidence, the Commission has amended Regulation SHO several times since 2005 to eliminate certain exceptions, strengthen certain requirements and reintroduce the price test restriction."
"“Naked” short selling is not necessarily a violation of the federal securities laws or the Commission’s rules. Indeed, in certain circumstances, “naked” short selling contributes to market liquidity. For example, broker-dealers that make a market in a security generally stand ready to buy and sell the security on a regular and continuous basis at a publicly quoted price, even when there are no other buyers or sellers. Thus, market makers must sell a security to a buyer even when there are temporary shortages of that security available in the market. This may occur, for example, if there is a sudden surge in buying interest in that security, or if few investors are selling the security at that time. Because it may take a market maker considerable time to purchase or arrange to borrow the security, a market maker engaged in bona fide market making, particularly in a fast-moving market, may need to sell the security short without having arranged to borrow shares. This is especially true for market makers in thinly traded, illiquid stocks as there may be few shares available to purchase or borrow at a given time."
"Rule 204 Close-out Requirement. Rule 204 requires brokers and dealers that are participants of a registered clearing agency to take action to close out failure to deliver positions. Closing out requires the broker or dealer to purchase or borrow securities of like kind and quantity. The participant must close out a failure to deliver for a short sale transaction by no later than the beginning of regular trading hours on the settlement day following the settlement date. If a participant has a failure to deliver that the participant can demonstrate on its books and records resulted from a long sale, or that is attributable to bona fide market making activities, the participant must close out the failure to deliver by no later than the beginning of regular trading hours on the third consecutive settlement day following the settlement date. If the position is not closed out, the broker or dealer and any broker or dealer for which it clears transactions (for example, an introducing broker) may not effect further short sales in that security without borrowing or entering into a bona fide agreement to borrow the security (known as the “pre-borrowing” requirement) until the broker or dealer purchases shares to close out the position and the purchase clears and settles. In addition, Rule 203(b)(3) of Regulation SHO requires that participants of a registered clearing agency must immediately purchase shares to close out failures to deliver in securities with large and persistent failures to deliver, referred to as “threshold securities,” if the failures to deliver persist for 13 consecutive settlement days."
https://www.sec.gov/investor/pubs/regsho.htm
Trading over the counter
"Unlike exchanges, OTC markets have never been a “place.” They are less formal, although often well-organized, networks of trading relationships centered around one or more dealers. Dealers act as market makers by quoting prices at which they will sell (ask or offer) or buy (bid) to other dealers and to their clients or customers."
https://www.imf.org/en/Publications/fandd/issues/Series/Back-to-Basics/Financial-Markets#:~:text=Trading%20over%20the%20counter&text=Dealers%20act%20as%20market%20makers,to%20their%20clients%20or%20customers.
"The process of purchasing or selling over-the-counter (OTC) stocks can be different from trading stocks listed on the New York Stock Exchange (NYSE) or the Nasdaq. This is because OTC stocks are, by definition, not listed on the exchange. Purchases of OTC securities are made through market makers who carry an inventory of stocks and bonds that they make available directly to buyers."
https://www.investopedia.com/ask/answers/buy-over-the-counter-stock/
When the MMs/Broker Dealers get Caught
FINRA fines Wedbush Securities for Regulation SHO violations
Maria Nikolova 0 Comments September 28, 2022
(note the time frames here, 1/1/2016 - 7/31/2020, 4.5 years of violations and 2 more years before FINRA took action, the SEC places much of the financial policing on SROs like FINRA )
The Financial Industry Regulatory Authority (FINRA) has fined Wedbush Securities for alleged violations of Regulation SHO.
During the periods of January 1, 2016 through July 31, 2020 and December 9, 2020 through April 7, 2021, Wedbush Securities, Inc. violated Regulation SHO Rules 204(a), (b), and (c) and FINRA Rule 2010 by failing to timely close out approximately 2,056 fail-to-deliver positions as required by Rule 204(a), and, on approximately 390 occasions failing to place securities in the “penalty box” as required by Rule 204(b) and failing to comply with the notice requirement of Rule 204(c).
The Securities and Exchange Commission adopted Regulation SHO to address concerns regarding persistent failures to deliver and potentially abusive “naked” short selling, e.g., the sale of securities that an investor does not own or has not borrowed.
*********************************************************
SEC Charges Chicago-Based Broker-Dealer with Violations of Regulation SHO
ADMINISTRATIVE PROCEEDING
File No. 3-20961
August 12, 2022 - The Securities and Exchange Commission today announced settled charges against Chicago-based registered broker-dealer IMC Chicago, LLC ("IMC") for violations of Rule 203(b)(1) of Regulation SHO through its Single-Dealer Platform ("SDP").
The SEC's order finds that from approximately June 2017 through November 2020, IMC violated Regulation SHO by executing millions of short sale trades through the SDP while improperly relying on the bona-fide market making exception to the "locate requirement" for short sales in Rule 203(b)
*****************************************************
June 15, 2020
Broker-Dealer Settles FINRA Charges for Reg SHO Violations
A broker-dealer settled FINRA charges for violating certain rules on short sales practices and related supervisory failures. The broker-dealer self-reported Regulation SHO concerns arising from system coding errors that resulted in its miscalculating the supply of available securities for approximately two years. Upon discovery of the issues, the broker-dealer halted relevant trading the next day and resumed trading in the relevant securities upon fixing the Regulation SHO issues.
FINRA found that the broker-dealer violated Rule 203(b)(1) of Regulation SHO ("Borrowing and Delivery Requirements") by executing short sale transactions without (i) producing a bona-fide arrangement to borrow securities or (ii) having "reasonable grounds" to believe that the securities could be borrowed by the delivery date.
*************************************************
FINRA And Citigroup Global Markets Not SHO Enough
December 20, 2022
FINRA the self-regulatory-organization apparently examined Citigroup Global Markets Inc. the FINRA Large Member firm during 2008 through 2022 because the regulator cited the firm's Reg SHO aggregation misconduct in three AWC settlements. Notably, the fines increased in each ensuing AWC. At some point, FINRA has to have an epiphany, however, that simply ratcheting up each ensuing fine on CGMI and other Large Member Firms doesn't accomplish anything. At best, the fines are an inconvenience for the violators. At worst, they are of no consequence. When it comes to Small Member Firms and the industry's hundreds of thousands of associated persons, FINRA selects sanctions seemingly designed to inflict pain. For the industry's big boys, well, y'know, it's more in the fashion of charging a modest toll on Wall Street.
2022 AWC Sanctions
In accordance with the terms of the 2022 FINRA CGMI AWC, FINRA imposed upon CGMI a Censure, $1,500,000 fine, and an undertaking to certify compliance with the supervisory issues cited.
*******************************************************
UBS fined US$2.5 million for Reg SHO failures Oct 6, 2022
FINRA has fined UBS Securities LLC US$2.5 million for Regulation SHO violations and for supervisory failings extending over a nine-year period.
The US regulatory watchdog, which works under the supervision of the Securities and Exchange Commission (SEC), ruled that UBS had failed to close out at least 5300 failure-to-deliver positions between 2009 and 2018.
Over the same timeframe, UBS had also routed or executed more than 73,000 short-sale trades without first having borrowed, or arranged to borrow, the shares.
FINRA also ruled that, between 2009 and August 2022, UBS’ supervisory systems and procedures were not “reasonably designed” to meet compliance with Reg SHO Rule 204.
Well.... there were 55 million shares Shorted Today and 50 million Buys at 5 Today.....
So you don't see the probability that the MMs Shorting all of those shares @ 5 prevented BIEL moving up to 6 until later in the day and dampened the Buying enthusiasm?
Only 10 million shares worth of Trading Today were legitimate, I own this many shares and I want to Sell them, Trades. The other 55 million shares were not owned by the Seller at the time of the Trade per FINRA's Daily Short Report.
Wondering Why BIEL Couldn't Hold On to 6 Today ?
Date .... Symbol . Short vol ... Total vol
20230605 | BIEL | 55205415 | 65321579
Pretty sure you don't get to .001 without traveling through .0005 and .0006
<<<<<<<<<<<< 3 ZEROS to the right of the decimal point >>>>>>>>>>>>>
Buys = 51.5 million shares
Sells = 7.3 million shares
Neutral = 6.3 million shares (.00045 SP)
Buys outnumber Sells 7 to 1 .
Go BIEL !!!
Yep Baha13, Today's 51 million in Buying is without news from BIEL
When the Update/PR hits things really start moving.
The 5 Bid Price has returned with a 5 million share Size.
6s are Printing, Go BIEL !!!
KT finally gets a Clue and Ups to 720 hours
UK ad is priced at 29.95 pound sterling which includes the UK VAT of 20%, so the US version should sell for about 29.95.
https://www.thinksport.co.uk/kt-tape-recovery-wave-720-hour-electromagnetic-therapy-device.html
Yep JGD, Buys Over Sells 16 to 1, BIEL Is On the Move
Buys = 50.5 million shares
Sells = 3.1 million shares
Neutral = 3.5 million shares
There is currently No Way Convertible Lenders can Sell Tens of Billions of Shares into the Market, there is not enough demand for anywhere near that many shares.
KW, PW and Dr Staelin know this.
<<<<<<<< most plausible way they get their loans repaid: R/S and conversion >>>>>>>>
The 2022 EOY Financials estimated 21.557 billion shares would be needed if IBEX Converted all of its $6.032 million in loans. BIEL closed at .0005 on the last Trading day of 2022. BIEL Trading at .005 would only need 2.155 billion shares to cover the same $6 million loan Conversion. But it has to be done organically by growing Sales not with a RS.
The only way KW, PW, and Dr Staelin get their loans paid back is to make BIEL profitable and increase its value by growing Sales.
Reverse Splits without evidence of a company turning itself around quickly find the SP heading back to the pre-RS price. Our friends at Endonovo provided an example of what not to do.
At the end of December 2019, with the SP at .0014 and 1 Billion Shares, ENDV enacted a '1 for 1,000 Reverse Split'.
This raised the SP to $1.40 and lowered the Share count to 1 Million.
It only took 3 months for ENDV's SP to plumet from $1.40 down to 17 cents at the end of March 2020, an 87% drop. ENDV had no positive story to tell.
Ya still don't get it
The only way KW, PW and RS get their loans repaid is when BIEL becomes profitable.
The last Conversion to Shares was 1/25/2022 by PW (St John's LLC). And what did PW do on 2/4/2022? She started making new Non-Convertible Loans to BIEL. As of the 2022 Financials she had made 7 of them totaling $106,000.
No other Conversions show up in the 2022 Financials.
Dr. Staelin, Chairman of the Board, also continues to make Loans to BIEL. In 2022 he made 9 Loans to BIEL totaling $448,000, all Non-Convertible Loans.
Doesn't sound like the COB is "screwing" anyone. He is providing vital financing and working toward BIEL's success.
Another Good Day For BIEL Longs, Up 11%, Buys Over Sells 9 to 1, 5 Close
Total Volume = 33.1 million shares
Buys = 25.2 million shares
Sells = 2.8 million shares
Neutral = 5.1 million shares @ .00045
Wow, 19 Million Share Buy at 9:35
$9,595 Investment in BIEL.
Go BIEL !!!
BIEL Up 50% on 79 Million Share Volume, Highest Volume in Over 3 Months
Buys = 60.3 Million Shares
Sells = 11 Million Shares
Neutral = 8 Million Shares (last Trade was Neutral, 200k shares @ .00045)
Sales-Track Shows Nothing Because It Does Not Exist
Years of touting Sales-Track and never even one document provided to prove its existence.
As the disclaimer states on this post,
"Everything I say and write is my opinion and my opinion only."